Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...

It’s got all the correct buzzwords for a hot biotech stock: machine learning, cell images, artificial intelligence. When Recursion Pharmaceutical went public at $18/share back in April, the stock ...